You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Scalable, Low-Cost, Ultrananocrystalline Diamond Electrochemical Process for the Destruction of Contaminants of Emerging Concern (CECs)

    SBC: Advanced Diamond TechNologies, Inc.            Topic: E

    This Small Business Innovation Research (SBIR) project will develop and ready for commercialization a scalable, low-cost process for purification of water containing Contaminants of Emerging Concern (CECs) using anodic oxidation with boron-doped ultrananocrystalline diamond (UNCD®) thin films. Resent research demonstrated that there is considerable potential for the development of electrochemica ...

    SBIR Phase I 2011 Environmental Protection Agency
  2. Electrical System for Rapid Bacterial Cultures

    SBC: TECHSHOT, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad, long-term objective of the proposed project Electrical System for Rapid Bacterial Cultures is to develop an automated electrical impedance analyzer for measuring bacterial growth in contaminated blood. Thepurpose of the System is to hasten the time to diagnose sepsis from 1-2 days down to a few hours. The specific aims of the project are to (1) bui ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Response Vaccines for Botulinum Neurotoxins

    SBC: Iterative Therapeutics Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Contrast agents for high-sensitivity ultrasound molecular imaging of tumor angiog

    SBC: TARGESON, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Molecular imaging techniques have strong potential in the setting of preclinical research, primarily for drug discovery and basic science in the field of cancer research. In particular, high-frequency ultrasound is a powerful imaging modality for phenotyping and monitoring the response to experimental therapy. Relative to other molecular imaging techniques, ult ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Screening of FoxA1-ER-DNA disruptors for development of breast cancer therapeutic

    SBC: Proteovista LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Estrogen receptor a (ERa) is the major therapeutic target for breast cancer, and ERa binding at target genes in breast cancer cells is guided by DNA binding pioneer factor proteins such as FoxA1. Although tamoxifen is asuccessful therapeutic for suppressing ER-mediated gene regulation, resistance to tamoxifen occurs in most breast cancer patients within five ye ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. A new paradigm for antibody-directed conjugates

    SBC: CENTROSE LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is among the most common and lethal cancers yet, the current standard of care for advanced stage NSCLC provides only modest improvements in overall survival or quality of life. Thus,there exists a significant unmet need for new effective therapies to treat NSCLC. Herein we describe an innovative new type of antibody drug conj ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Multifunctional Peptides for (MRI) Imaging

    SBC: CDG THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Our overall goal is to expand the role of CPPs in molecular imaging at the patient level using large animal models of human tumors and a peptide agent that inherently provides 1) preferential access to a wide variety ofhuman solid (and hematologic) tumor cells, 2) an increased intracellular concentration (2-12 fold) over histologically matched normal cells, and ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a plectin-1 targeted imaging agent for the detection of pancreatic can

    SBC: iTi Health            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is an intractable clinical problem, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. Currently, the standarddiagnostic course includes CT or MRI scans which do not have optimal sensitivity and specificity for accurately diagnosing and determining resec ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. High Throughput Method to Assess SNP Functionality in Prostate Cancer

    SBC: Proteovista LLC            Topic: NCI

    DESCRIPTION (provided by applicant): A critical unmet need in implementing personalized medicine is the ability to sort through the millions of single nucleotide polymorphisms (SNPs) present in the human genome and to pinpoint which of these DNA variations are causative in disease. A key under-studied function of SNPs is their ability to generate or disrupt genomic binding sites for transcription ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Intra-Oral drug-eluting adhesive film

    SBC: AKINA, INC.            Topic: NIDCR

    DESCRIPTION (provided by applicant): The objective of this Phase I study is to develop an intra-oral, adhesive film which can cover and protect various mouth sores and deliver low doses of pain relieving lidocaine and anti-inflammatory doxycycline to thesore site. In particular, we will focus on developing the adhesive film for treating canker sores, which is a ubiquitous problem affecting many p ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government